GBA1 and Parkinson disease: A hopeful future and availability of neuroprotective therapies may influence the way in which we inform GD patients and GBA1 variant carriers on their PD risk and will, therefore, require a new reflection on how to deal with the delicate issue of communicating the risk of this neurodegenerative disease.